Impax Asset Management significantly reduced its position in Regeneron Pharmaceuticals by 53% in the first quarter, selling 1 ...

Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...